Clinical trials: Sclerosis
Multiple Sclerosis
Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods
In Multiple Sclerosis (MS) gait disorders represent one of the most disabling aspect that strongly influence patient quality of life. The improvement of walking ability is a primary goal for rehabilitation treatment.
- Trial name
- NCT02291107
- Testing
- Lokomat (Hocoma, Zurich, Switzerland), Conventional Physiotherapy
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Habilita, Ospedale di Sarnico
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Relapsing Multiple Sclerosis
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to…
- Trial name
- NCT07220252
- Testing
- Ublituximab, Fingolimod
- Where
- 6 sites in United States, Poland and 1 more
- Volunteers
- 240 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)
The aim of this study is to assess the efficacy of endovascular treatment (balloon angioplasty and/or stenting) for the improvement of clinical symptoms in multiple sclerosis patients.
- Trial name
- NCT01264848
- Testing
- balloon angioplasty and/or stenting
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Euromedic Specialist Clinics, Poland
Epilepsy, Epilepsy, Temporal Lobe
Early Surgical Intervention to Treat Epilepsy
The purpose of this trial is to compare the effectiveness of early surgical intervention for mesial temporal lobe epilepsy to continued treatment with antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsy, Temporal Lobe, Seizures
- Trial name
- ERSET (NCT00040326)
- Testing
- anteromesial temporal resection, antiepileptic drugs
- Where
- 12 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of California, Los Angeles
Upper Extremity Impairments, Cerebral Palsy (CP)
Obi Medical Robot: Evaluating Effectiveness Related to Usability
This mixed-methods usability study evaluates the effectiveness of the Obi Gen 3 robotic feeding device in meeting user needs among providers, caregivers, and patients.
- Conditions
- Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
- Trial name
- NCT07151950
- Testing
- One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Desin LLC
Lymphoma
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and vinorelbine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00006760
- Testing
- filgrastim, ifosfamide, vinorelbine tartrate
- Where
- 114 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
Multiple Sclerosis, Clinically Isolated Syndrome
Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis
This observational study investigates the efficacy and safety of immunoadsorption versus plasmapheresis in 60 patients with relapse in Multiple Sclerosis and Clinically isolated syndrome who do not fully recover after a high…
- Trial name
- NCT02671682
- Testing
- Immunoadsorption, Plasmapheresis
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Albert Christian Ludolph, Prof.
Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
- Trial name
- Breakfree-SSc (NCT07335562)
- Testing
- BMS-986353, Fludarabine, Cyclophosphamide
- Where
- 56 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Pediatric Multiple Sclerosis
Exercise Training in Pediatric-Onset Multiple Sclerosis Patients
Multiple sclerosis is one of the leading causes of disability in young adults. It is known that patients with pediatric onset multiple sclerosis (POMS) experience their first demyelinating attack before the age of 18.
- Trial name
- NCT04660227
- Testing
- Exercise Trainning, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Istanbul University - Cerrahpasa
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
Background: Transcranial Magnetic Stimulation (TMS) is a technique based on the principles of electromagnetic induction. It applies pulses of magnetic radiation that penetrate the brain tissue, and it is a non-invasive, painless…
- Trial name
- NCT04062331
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Volunteers
- 90 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
ALS
National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank
This study will identify living veterans with amyotrophic lateral sclerosis (ALS) through a national registry that is being developed. Diagnosis of ALS will be verified by study neurologists via medical record review.
- Trial name
- ALS Registry (NCT00076154)
- Where
- United States
- Volunteers
- 2,121 people
- Sponsor
- US Department of Veterans Affairs
Stroke, Brain Injuries
Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation
Postural and balance disorders are common in neurological disorders. They are often associated with reduced mobility and fear of falling, which strongly limit independent activities of daily living (ADL), compromise the quality…
- Conditions
- Stroke, Brain Injuries, Mild Cognitive Impairment, Parkinson Disease
- Trial name
- NCT04691102
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Tuberous Sclerosis Complex
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction…
- Trial name
- NCT04112537
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Hodgkin Lymphoma
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00002561
- Testing
- bleomycin sulfate, dacarbazine, doxorubicin hydrochloride
- Where
- 22 sites in Canada, Italy and 1 more
- Volunteers
- 405 people
- Sponsor
- NCIC Clinical Trials Group
Relapsing Remitting Multiple Sclerosis
Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
1.to evaluate the potential role of the optic nerve diameter ( OND determined by ultrasonography and and visual nerve function by visual evoked potential as a biomarker of early axonal loss and disability in patients with…
- Trial name
- NCT06435962
- Testing
- sonography
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberous Sclerosis Complex
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy.
- Trial name
- NCT05323734
- Testing
- Ganaxolone
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Marinus Pharmaceuticals